Cargando…

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer

BACKGROUND: The presence of tumour-infiltrating lymphocytes (TILs) is a favourable prognostic factor in patients with early breast cancer. Programmed cell death-1 (PD-1) and its ligand PD-L1 are associated with a variety of adverse features. The purpose of this study was to clarify the relationships...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitano, Atsuko, Ono, Makiko, Yoshida, Masayuki, Noguchi, Emi, Shimomura, Akihiko, Shimoi, Tatsunori, Kodaira, Makoto, Yunokawa, Mayu, Yonemori, Kan, Shimizu, Chikako, Kinoshita, Takayuki, Fujiwara, Yasuhiro, Tsuda, Hitoshi, Tamura, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	ESMO Open 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519809/ https://www.ncbi.nlm.nih.gov/pubmed/28761741 http://dx.doi.org/10.1136/esmoopen-2016-000150

Ejemplares similares

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site
por: Sato, Jun, et al.
Publicado: (2019)

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
por: Kodaira, Makoto, et al.
Publicado: (2018)

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy
por: Iizumi, Sakura, et al.
Publicado: (2017)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers
por: Shimoi, Tatsunori, et al.
Publicado: (2021)

TERT promoter hotspot mutations in breast cancer
por: Shimoi, Tatsunori, et al.
Publicado: (2017)

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system
por: Shimoi, Tatsunori, et al.
Publicado: (2018)

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2018)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
por: Tanabe, Yuko, et al.
Publicado: (2017)

Primary Yolk Sac Tumor of the Omentum: A Case Report and Literature Review
por: Harano, Kenichi, et al.
Publicado: (2012)

Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer
por: Yazaki, Shu, et al.
Publicado: (2022)

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer
por: Tamura, Kenji, et al.
Publicado: (2018)

Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal
por: Yonemori, Kan, et al.
Publicado: (2012)

Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging
por: Ryu, Shoraku, et al.
Publicado: (2020)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)

Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
por: Watase, Chikashi, et al.
Publicado: (2021)

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients
por: Tanabe, Yuko, et al.
Publicado: (2020)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
por: Kitadai, Rui, et al.
Publicado: (2021)

Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping
por: Kojima, Yuki, et al.
Publicado: (2023)

Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression
por: Hanamura, Toru, et al.
Publicado: (2022)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma
por: Kojima, Yuki, et al.
Publicado: (2023)

Long non‐coding NR2F1‐AS1 is associated with tumor recurrence in estrogen receptor‐positive breast cancers
por: Sanchez Calle, Anna, et al.
Publicado: (2020)

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
por: Yazaki, Shu, et al.
Publicado: (2022)

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
por: Kitano, Shigehisa, et al.
Publicado: (2020)

Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs
por: Hata, Tomomi, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy
por: Watanabe, Sho, et al.
Publicado: (2023)

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
por: Takahashi, Shunji, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m63o1v4nitmpbi7c7634ei9jij